Esketamine, developed by Johnson & Johnson, is a nasal spray that delivers the active ingredients of ketamine, a recreational drug from the 1980s and 1990s. It could be a new treatment for severe
depression and suicidal ideation after an expert panel recommended that federal regulators approve it. “The Food and Drug Administration typically follows the recommendations of its expert
panels,” according to
The New York Times.
Read the whole story at The New York Times »
